Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study

BACKGROUND: Small-cell lung cancer (SCLC) remains an aggressive cancer with short-term survival due to limited therapeutic options. Apatinib is a small-molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor-2. This study aimed to investigate the effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yanjun, Huang, Zhiyu, Lu, Hongyang, Yu, Xinming, Li, Yuping, Li, Wenfeng, Chen, Jun, Chen, Ming, Gong, Lei, Chen, Kaiyan, Qin, Jin, Xu, Xiaoling, Jin, Ying, Zhao, Jun, Shi, Xun, Han, Na, Xie, Fajun, Zhang, Peng, Xu, Weizhen, Fan, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889407/
https://www.ncbi.nlm.nih.gov/pubmed/31523058
http://dx.doi.org/10.1038/s41416-019-0583-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889407/
https://www.ncbi.nlm.nih.gov/pubmed/31523058
http://dx.doi.org/10.1038/s41416-019-0583-6

Ejemplares similares